Patterns of use and safety of ibrutinib in real-life practice.

Marion AlloucheryCécile TomowiakStéphanie GuidezVincent DelwailPaul DelaunayClaire Lafay-ChebassierFrancesco SalvoMarie-Christine Pérault-Pochat

Published in: British journal of clinical pharmacology (2020)

This study found a high cumulative incidence of ibrutinib-associated SADRs within the first year of treatment. In view of the risk of SADR, patients aged ≥80 years or treated for CLL deserve special attention.

Keyphrases

end stage renal disease
chronic lymphocytic leukemia
newly diagnosed
ejection fraction
chronic kidney disease
primary care
peritoneal dialysis
risk factors
prognostic factors
working memory
patient reported outcomes
quality improvement